PMID: 22413863

Authors:

Flygare J, Beresini M, Budha N, Chan H, Chan I, Cheeti S, Cohen F, Deshayes K, Doerner K, Eckhardt G, Elliott LO, Feng B, Franklin M, Reisner S, Gazzard L, Halladay J, Hymowitz SG, La H, Lorusso P, Maurer B, Murray L, Plise E, Quan C, Stephan JP, Young S, Tom J, Tsui V, Um J, Varfolomeev E, Vucic D, Wagner A, Wallweber H, Wang L, Ware J, Wen Z, Wong H, Wong J, Wong M, Wong S, Yu R, Zobel K, Fairbrother WJ

Title:

The Discovery of a Potent Small-Molecule Antagonist of Inhibitor of Apoptosis (IAP) Proteins and Clinical Candidate for the Treatment of Cancer (GDC-0152).

Journal:

J Med Chem. 2012 Mar 13.

Abstract:

A series of compounds were designed and synthesized as antagonists of cIAP1/2, ML-IAP, and XIAP based on the N-terminus, AVPI, of mature Smac. Compound 1 (GDC-0152) has the best profile of these compounds; it binds to the XIAP BIR3 domain, the BIR domain of ML-IAP, and the BIR3 domains of cIAP1 and cIAP2 with Ki values of 28, 14, 17 and 43 nM, respectively. These compounds promote degradation of cIAP1, induce activation of caspase-3/7, and lead to decreased viability of breast cancer cells without affecting normal mammary epithelial cells. Compound 1 inhibits tumor growth when dosed orally in the MDA-MB-231 breast cancer xenograft model. Compound 1 was advanced to human clinical trials and it exhibited linear pharmacokinetics over the dose range (0.049 to 1.48 mg/kg) tested. Mean plasma clearance in humans was 9 +/- 3 mL/min/kg and volume of distribution was 0.6 +/- 0.2 L/kg.